anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Binge eating disorder is the most prevalent eating disorder and affects both men and women at comparable rates unlike anorexia nervosa and bulimia nervosa. Given that binge eating and obesity are strongly associated, binge eating treatments should aim to reduce binge eating as well as weight. However, most binge eating interventions do not produce lasting weight loss. Recent research has shown computer-based response inhibition training with high-calorie foods reduces reward region response to and attentional bias for the training foods, decreases training food intake, increases inhibitory control, and produces weight loss in overweight adults. There is evidence that the weight loss effects from such response training persist through 6-month follow-up. Further, binge eating has been associated with increased food-related impulsivity and increased activation in a reward-processing brain region to high-calorie foods. Prior research suggests that food response training may be an effective intervention for binge eating that teaches automatic self-control in response to high-calorie foods which in turn, reduces binge eating and produces weight loss. This study will examine the effectiveness of food response training interventions in reducing binge eating and weight among adults engaged in binge eating.

The goals of this study are to: (1) test the hypothesis that adults who complete the food response trainings will show significantly greater reductions in binge eating frequency and in body mass index (BMI) compared to generic response training from pretest to posttest and at 3-month follow up, (2) to determine whether one of the food response trainings is more effective in binge eating frequency and reducing BMI from pretest to posttest and at 3-month follow up, and (3) test whether a reduction in valuation of the high-calorie versus low-calorie foods (willingness to pay for the pictured foods) and/or behavioral improvement of inhibitory control during the training tasks mediate the effects of the various trainings on reductions in binge frequency and body mass index.
An antipoliomyelitis vaccine is prepared by inactivating the poliomyelitis virus by treatment with hydroxylamine in a concentration of 0.01 to 5.0 mols/litre and (a) a pH of 4.5 to 7.0 and preferably 6.0 and temperature of 4 DEG  to 40 DEG C. or (b) a pH of 6.5 to 7.0 and preferably 7.0 and a temperature of 30 DEG  to 40 DEG C. and preferably 37 DEG C., allowing the hydroxylamine to act on the viruses, which may be contaminated with Simian virus 40, until the latter is free from infectious viruses, binding unreacted hydroxylamine with a carbonyl compound capable of forming an oxime therewith, and processing the inactivated virus into a vaccine in known manner.  Prior to the inactivation step, the virus suspension may be concentrated.  The oxime, if soluble, may be removed by dialysis and, if insoluble, it may be removed by filtration or centrifugal action.  Specified carbonyl compounds are acetone, acetylacetone, acetonyl acetone, acetoacetic acid ethyl ester or acetoacetic acid methyl ester.  Preferably 1-10 times the stoichiometrical amount of carbonyl compound, calculated on the hydroxylamine used, may be used for binding unreacted hydroxylamine. Conventional adjuvants for increasing antibody formation, e.g. aluminium hydroxide or phosphate, may be present.
The present invention relates to a glucosamine-containing enteric-coated tablet composition. The glucosamine-containing enteric-coated tablet composition comprises glucosamine as a main ingredient. Micro-crystallized cellulose, silicon dioxide, lactose, dextrin, green mussel powder, crystallized cellulose, Kollidon, shark cartilage powder, lactose, starchy, calcium, collagen, manganese sulfate, zinc oxide, vitamin or stearic acid, magnesium, and so on as an excipient. A pre-mixture is formed by pre-mixing glucosamine and the excipient. The formed pre-mixture is manufactured into a bare tablet by using a tablet manufacturing device. Afterwards, Eudragit is used as a coating solution. Accordingly, crumbling in a stomach having an acidic condition is significantly reduced. The tablet composition crumbles in an intestine. In addition, when a user takes the tablet composition, an effect of reducing side effects in a stomach and an intestine is significantly increased. Moreover, when pharmaceutical and health functional food is coated by using the coating agent of the present invention, 3-5 wt% of Eudragit in the composition is coated with respect to the bare tablet.
Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
The invention discloses a temozolomide brain-targeting pharmaceutical composition and application thereof. The pharmaceutical composition provided by the invention contains a therapeutic effective dose of temozolomide, an absorbefacient and a pharmaceutical carrier. The invention also provides a pharmaceutical composition which contains a therapeutic effective dose of temozolomide, a stabilizer and a pharmaceutical carrier. The invention further provides the application of the pharmaceutical compositions provided by the invention in the preparation of drugs for intranasal administration. The compositions provided by the invention can be used as nasal powder. The temozolomide nasal powder provided by the invention is formed by the temozolomide, the pharmaceutical carrier and the stabilizer or the absorbefacient and is a preparation which reaches the brain to treat brain tumors through the absorption of nasal mucosa.
The present invention relates to a cell aging inhibiting composition including a Chrysanthemum zawadskii Herbich var. lucidum (Nakai) T. Lee extract as an effective component. More particularly, the present invention relates to health functional food and a pharmaceutical composition containing a Chrysanthemum zawadskii Herbich var. lucidum (Nakai) T. Lee extract. The Chrysanthemum zawadskii Herbich var. lucidum (Nakai) T. Lee extract of the present invention can treat or prevent cell aging-related diseases and inflammatory diseases.
PURPOSE OF REVIEW: The prevalence of obesity continues to rise steadily. While obesity management typically relies on dietary and lifestyle modifications, individual responses to these interventions vary widely. Clinical guidelines for overweight and obesity stress the importance of personalized approaches to care. This review aims to underscore the role of precision nutrition in delivering tailored interventions for obesity management. RECENT FINDINGS: Recent technological strides have expanded our ability to detect obesity-related genetic polymorphisms, with machine learning algorithms proving pivotal in analyzing intricate genomic data. Machine learning algorithms can also predict postprandial glucose, triglyceride, and insulin levels, facilitating customized dietary interventions and ultimately leading to successful weight loss. Additionally, given that adherence to dietary recommendations is one of the key predictors of weight loss success, employing more objective methods for dietary assessment and monitoring can enhance sustained long-term compliance. Biomarkers of food intake hold promise for a more objective dietary assessment. Acknowledging the multifaceted nature of obesity, precision nutrition stands poised to transform obesity management by tailoring dietary interventions to individuals' genetic backgrounds, gut microbiota, metabolic profiles, and behavioral patterns. However, there is insufficient evidence demonstrating the superiority of precision nutrition over traditional dietary recommendations. The integration of precision nutrition into routine clinical practice requires further validation through randomized controlled trials and the accumulation of a larger body of evidence to strengthen its foundation.
UNLABELLED: This study investigated the changes in brain gray and white matter structure in SMA patients and their correlation with the severity of the disease. A total of 43 SMA patients (including 22 type II and 21 type III SMA patients) and 37 healthy controls were evaluated by MRI. The gray matter volume, gray matter thickness, gray matter surface area, and white matter volume of designated brain regions automatically segmented by FreeSurfer, were compared. We evaluate clinical characteristics of SMA and study the correlation between clinical characteristics and structural changes. SMA showed significant bilateral cortical superficial area loss in the frontal, parietal, and temporal lobes and global white matter volume decreases. Moreover, these patients were also found with an increased mean thickness of entire brain and right gray matter. An increased right postcentral gyrus superficial area, right central sulcus volume, and white matter volume of the right postcentral were associated with higher HFMSE scores.
CONCLUSION: Type 2 and 3 children SMA had extensive, multifocal, symmetrical gray and white matter alterations. Postcentral gyrus degeneration of SMA was associated with the severity of muscular atrophy. The lack of SMN protein possibly interacted with cerebellar structural changes in somatosensory areas.
WHAT IS KNOWN: • MRI has found brain changes in SMA patients, however, there is no unified conclusion and lack of correlation with clinical degree in children SMA with type 2-3.
WHAT IS NEW: • Type II and II children SMA had extensive, multifocal, symmetrical gray and white matter alterations. Postcentral gyrus degeneration of SMA was associated with the severity of muscular atrophy. Cerebellar structural changes in somatosensory areas may attribute to the lack of SMN protein.
<P>PROBLEM TO BE SOLVED: To provide an antigenic composition and/or delivery system to respond to predetermined requests or provide public at least with a useful option.  <P>SOLUTION: This invention relates to an antigenic composition and a method for immunizing animals using the same. The antigenic composition comprises a lipid formulation most usually in a solid form and at least one kind of antigenic component. A preferred antigenic component is a living microorganism. The composition is formulated for oral administration in a preferred embodiment.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-clonic seizures in patients 2 years old and older was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing a single dosage of topiramate and placebo.

Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topiramate or placebo. Patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least three primary generalized tonic-clonic seizures during the baseline phase were randomly assigned to placebo or topiramate in addition to their other AEDs.

Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg per day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg per day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.
<P>PROBLEM TO BE SOLVED: To provide a method for suppressing expression of a target protein in the local region of a living body by a simple method and to provide an apparatus system for carrying out the method.  <P>SOLUTION: The method for suppressing expression of the protein comprises carrying out intracellular transduction of siRNA by applying an electric pulse to a nerve-limited region to remarkably suppress only expression of the target protein in the local region. The siRNA can be transduced into a cell even when relatively weak voltage is applied to the siRNA and damage to living bodies can be reduced by combining two kinds of pulses which are a pulse for perforating a cell membrane and a pulse for intercellular transduction. According to the method, pathologic change is not recognized in a tissue in which siRNA is transduced and influence on expression of a protein other than the target protein is not also recognized. The method enables not only utilization to analysis of genetic function, but also application to treatment, etc.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To obtain a coating agent containing a mixture of a complex consisting of an amphoteric surfactant and/or semipolar surfactant and nigher fatty acid and volatile solvent, capable of making skin, hair, cloth and leather water-repellent and giving smooth feeling thereto and reduced in irritation. CONSTITUTION:The objective coating agent containing a complex obtained by blending an amphoteric surfactant (especially preferably amidebetaine type amphoteric surfactant or amidesulfobetaine type amphoteric surfactant) and/or a semipolar surfactant (especially preferably tert. amine oxide type semipolar surfactant) with a higher fatty acid (e.g. lauric acid or myristic acid) and volatile solvent (e.g. pentane, methanol or diethyl ketone). The coating agent can make the coated face water-repellent and provide smooth feeling to the face and, as necessary, can wash the face with a cleaning agent, etc.
BACKGROUND: Despite breakthroughs in stroke treatment, some patients still experience large infarctions of the cerebral hemispheres resulting in mass effect and tissue displacement. The evolution of mass effect is currently monitored using serial computed tomography (CT) imaging. However, there are patients who are ineligible for transport, and there are limited options for bedside monitoring of unilateral tissue shift.
METHODS: We used fusion imaging for overlaying transcranial color duplex with CT angiography. This method allows overlay of live ultrasound on top of CT or magnetic resonance imaging scans. Patients with large hemispheric infarctions were eligible to participate. Position data from the source files were used and matched with live imaging and correlation to magnetic probes on the patient's forehead and ultrasound probe. Shift of cerebral parenchyma, displacement of the anterior cerebral arteries, basilary artery and third ventricle were analyzed, as well as pressure on the midbrain, and the displacement of the basilar artery on the head were analyzed. Patients received multiple examinations in addition to standard care of treatment with CT imaging.
RESULTS: The sensitivity for diagnosing a shift of 3 mm with fusion imaging was 100%, with a specificity of 95%. No side effects or interactions with critical care equipment were recorded.
CONCLUSIONS: Fusion imaging is an easy method to access and acquire measurements for critical care patients and follow-up of tissue and vascular displacement after stroke. Fusion imaging may be a decisive support for indicating hemicraniectomy.
The present invention relates to physique strengthening health liquor (wine) and a preparing method thereof. The physique strengthening health liquor (wine) comprises the components of the following weight proportion: 3 to 4 parts of spirit with more than 60 DEG, 0.005 to 0.01 part of solomonseal rhizome, 0.006 to 0.012 part of curculigo rhizome, 0.0006 to 0.0012 part of dog testes and penis (big), 0.00025 to 0.00064 part of antler, 0.0003 to 0.0009 part of gecko (big), 0.003 to 0.006 part of tortoise plastron, 0.008 to 0.016 part of lanatechead saussurea herb with flower, 0.005 to 0.008 part of false wintergreen, 0.007 to 0.015 part of Chinese wolfberry, 0.008 to 0.012 part of meat boschniakia rossica, 0.005 to 0.009 part of Chinese dodder herb seed, 0.006 to 0.012 part of epimedium, 0.007 to 0.013 part of fleece-flower root, 0.004 to 0.009 part of licorice root, 0.007 to 0.015 part of ginseng and 0.007 to 0.013 part of cynomorium. The present invention comprises the components of the solomonseal rhizome, the curculigo rhizome, the dog testes and penis, the antler, the gecko, the tortoise plastron, the lanatechead saussurea herb with flower, the false wintergreen, the Chinese wolfberry, the meat boschniakia rossica, the Chinese dodder herb seed, the epimedium, the fleece-flower root, angelica, the licorice root, the ginseng, the cynomorium and the spirit with 60 DEG. The present invention health functions of blood circulation promotion, vital energy invigoration, Yin and Yang regulation and invigoration and beatufying; the present invention has peculiar efficacy for spermatorrhea, premature ejaculation, lumbago, leg weakness, body weakness, menoxenia, neurasthenia, upset, insomnia, memory decline and weak heslth for old age. After sexual life, the present invention can quickly restore lost sperms in a short time. Vital energy is the best of the present invention.
Human placentral lactogen (HPL) was produced by hybridoma cells following cell growth as an implant in an animal. Thus, cells from a human choriocarcinoma were fused with Namalevaf human leukenic lymphoblasts. After cloning, the selected cells were implanted i.p. in adult nude mice. After 5 wk, the resulting massive tumors were removed and disaggregated. The cells were incubated in pH 7.2 Earle 199 medium contg. 10% fetal calf  serum and 30mM arginine at 35≰C for 20 hrs. and then ultrasonicated. The yield of HPL was 340 μg/ml.
Abstract Materials are described that nonspecifically amplify the immune response of a person or mammal to antigens to which the person or mammal was previously or is concomitantly exposed.  The materials are low M.W. polypeptides and derivatives thereof.  Also described are methods and pharmaceutical compositions for the use of the materials in reconstituting immune system function in per-sons suffering from hypoimmune conditions such as AIDS and ARC, and in correcting other immune deficiency imbalances such as that seen in rheumatoid arthritis.     Materials of particular interest are a dipeptide containing Tyr-Gly, a tripeptide containing Tyr-Gly-Gly, and derivatives thereof.     High pressure liquid chromatography processes are described for the extraction and purification of said materials, from leuko-cyte dialysates derived from human white blood cells.  A process for purification of synthetically-derived such material is also described.
AIMS: This study compares the re-revision rate and mortality following septic and aseptic revision hip arthroplasty (rTHA) in registry data, and compares the outcomes to previously reported data.
METHODS: This is an observational cohort study using data from the German Arthroplasty Registry (EPRD). A total of 17,842 rTHAs were included, and the rates and cumulative incidence of hip re-revision and mortality following septic and aseptic rTHA were analyzed with seven-year follow-up. The Kaplan-Meier estimates were used to determine the re-revision rate and cumulative probability of mortality following rTHA.
RESULTS: The re-revision rate within one year after septic rTHA was 30%, and after seven years was 34%. The cumulative mortality within the first year after septic rTHA was 14%, and within seven years was 40%. After multiple previous hip revisions, the re-revision rate rose to over 40% in septic rTHA. The first six months were identified as the most critical period for the re-revision for septic rTHA.
CONCLUSION: The risk re-revision and reinfection after septic rTHA was almost four times higher, as recorded in the ERPD, when compared to previous meta-analysis. We conclude that it is currently not possible to assume the data from single studies and meta-analysis reflects the outcomes in the 'real world'. Data presented in meta-analyses and from specialist single-centre studies do not reflect the generality of outcomes as recorded in the ERPD. The highest re-revision rates and mortality are seen in the first six months postoperatively. The optimization of perioperative care through the development of a network of high-volume specialist hospitals is likely to lead to improved outcomes for patients undergoing rTHA, especially if associated with infection.
<P>PROBLEM TO BE SOLVED: To provide a composition for foods and drinks in which S-adenosylmethionine is stably retained for a long period of time, and a method for stabilizing the S-adenosylmethionine.  <P>SOLUTION: This invention provides a composition for foods and drinks containing phytic acid and S-adenosylmethionine. The S-adenosylmethionine is stabilized by phytic acid in the composition. This invention also provides a composition for foods and drinks containing a combination of S-adenosylmethionine, phytic acid and dextrin. The combined use of phytic acid with dextrin exhibits a greater stabilization effect as compared to the use of phytic acid alone. The dextrin is preferably a γ-cyclic dextrin and more preferably a mixture of a cyclic dextrin and a non-cyclic dextrin.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The present invention relates to a composition for preventing or treating sterility or infertility comprising a sialylated Tn antigenic carbohydrate, or an activation agent of the antigen as an active component. Further, the present invention relates to a pharmaceutical composition for contraception comprising an inhibitor of a sialylated Tn antigenic carbohydrate, or an expression or active inhibitor of enzymes which synthesize the antigen. Further, the present invention relates to a marker composition for measuring pregnancy possibility or pregnancy efficiency comprising a sialylated Tn antigenic carbohydrate. Further, the present invention relates to a method for screening a sterility or infertility treatment agent, or an anticonceptive using sialylated Tn sugar chains. A sialylated Tn antigen according to the present invention has a close relation with implantation of pregnancy. Therefore, a sialylated Tn antigen according to the present invention is capable of being used as a sterility treatment agent or an anticonceptive, and is used to measure pregnancy possibility or pregnancy efficiency. Further, a sialylated Tn antigen according to the present invention is capable of being used as a method for screening the sterility treatment agent or the anticonceptive.
All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
This study is designed to determine the cause of post operative hyponatremia in renal transplant patients at the Mayo Clinic of Florida. Recently, the investigators have noted a trend in post-operative hyponatremia (low serum sodium) in patients who are recipients of both living donor and cadaveric kidneys. To improve the quality of care of this patient population, the investigators propose the investigation of the sources of this decline in serum sodium levels to determine if this is preventable. The investigators propose that a potential source of post-operative hyponatremia may be related to intra-operative factors. Currently, the intravenous fluid of choice used intra-operatively is 0.45% normal saline. The investigators hypothesize that this fluid choice contributes to post-operative hyponatremia.

To further investigate this the investigators will perform a retrospective review using the renal transplant database to collect data regarding pre-operative diagnoses, co-morbidities, and method of dialysis used in the pre-transplant period. Pre-operative serum sodium level will be compared to post-operative serum sodium levels. Data including post-operative complications, need and reasons for post-operative dialysis, and hospital course will also be collected. Once the data are analyzed and a primary source or sources are identified as causative agents for post-operative hyponatremia, an intervention to prevent a decline in serum sodium post-operatively will be planned for future study.